Promising Advances in Parkinson’s Disease Treatment by Anavex Life Sciences
Anavex Life Sciences has recently announced significant progress in the treatment of Parkinson’s disease dementia (PDD) through its investigational drug, blarcamesine. The company’s Phase 2 extension study, despite initial setbacks due to the COVID-19 pandemic, demonstrated notable efficacy and safety over a 48-week period. Patients who participated in the open-label extension of the study […]